Outcome After Azacitidine Treatment in Patients with High-Risk Myeolodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia – A Single Center Experience (Preliminary Data)
Authors
A. Anastasova-Postadzhiyan
Clinic of Hematology, Military Medical Academy, Sofia, Bulgaria
A. Nedeva
Clinic of Hematology, Military Medical Academy, Sofia, Bulgaria
I. Nikolov
Clinic of Hematology, Military Medical Academy, Sofia, Bulgaria
I. Kindekov
Clinic of Hematology, Military Medical Academy, Sofia, Bulgaria
Y. Kuyumdzhieva
Clinic of Hematology, Military Medical Academy, Sofia, Bulgaria
N. Petkova
Clinic of Hematology, Military Medical Academy, Sofia, Bulgaria
E. Vikentieva
Laboratory of clinical immunology, Military Medical Academy, Sofia, Bulgaria
M. Lubomir
Laboratory of Cytogenetics and Molecular Biology, Military Medical Academy – Sofia, Bulgaria
J. Raynov
Clinic of Hematology, Military Medical Academy, Sofia, Bulgaria
Language: English
Page range: 38 - 43
Accepted on: Dec 20, 2019
Published on: Nov 24, 2020
Published by: Medical University - Sofia
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2020 V. Varbanova, A. Anastasova-Postadzhiyan, A. Nedeva, I. Nikolov, I. Kindekov, Y. Kuyumdzhieva, N. Petkova, E. Vikentieva, M. Lubomir, J. Raynov, published by Medical University - Sofia
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.